KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Abbott Laboratories (ABT) Operating Expenses (2016 - 2026)

Abbott Laboratories' Operating Expenses history spans 18 years, with the latest figure at $9.8 billion for Q1 2026.

  • On a quarterly basis, Operating Expenses rose 13.32% to $9.8 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $37.4 billion, a 6.3% increase, with the full-year FY2025 number at $36.3 billion, up 3.27% from a year prior.
  • Operating Expenses hit $9.8 billion in Q1 2026 for Abbott Laboratories, up from $9.2 billion in the prior quarter.
  • Over the last five years, Operating Expenses for ABT hit a ceiling of $9.8 billion in Q1 2026 and a floor of $8.2 billion in Q1 2023.
  • Historically, Operating Expenses has averaged $8.8 billion across 5 years, with a median of $8.8 billion in 2024.
  • Biggest five-year swings in Operating Expenses: decreased 8.29% in 2023 and later grew 13.32% in 2026.
  • Tracing ABT's Operating Expenses over 5 years: stood at $8.8 billion in 2022, then dropped by 3.71% to $8.5 billion in 2023, then increased by 7.11% to $9.1 billion in 2024, then grew by 1.6% to $9.2 billion in 2025, then grew by 6.64% to $9.8 billion in 2026.
  • Business Quant data shows Operating Expenses for ABT at $9.8 billion in Q1 2026, $9.2 billion in Q4 2025, and $9.3 billion in Q3 2025.